AbbVie Inc.
AbbVie Inc.
- Market cap
- $505.47B
- P/E ratio
- 49.15
Your view on ABBV
Overview
What the company does, where it operates, and who runs it.
About AbbVie Inc.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Robert A. Michael CPA
- Headquarters
- 1 North Waukegan Road, North Chicago, IL, US
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Robert A. Michael CPA
- Headquarters
- 1 North Waukegan Road, North Chicago, IL, US
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.
The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic.
In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for AbbVie Inc. from FRC's valuation model, read against the market price. ABBV last traded at $285.96, 49.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for AbbVie Inc.. Starting points for AbbVie Inc.: P/E 49.2, EPS $5.84, beta 0.28 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for AbbVie Inc.. AbbVie Inc. paid $6.92 per share over the last year — a 2.4% yield at the current $285.96 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for AbbVie Inc.. Trailing twelve-month EPS for AbbVie Inc. stands at $5.84. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
25 firms, last 12 months- Strong Buy0
- Buy21
- Hold4
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $3.89 | $3.44 | $14.01 | $16.26 |
| Lowest estimate | $3.80 | $3.41 | $13.93 | $15.49 |
| Highest estimate | $4.02 | $3.47 | $14.17 | $16.57 |
| Number of analysts | 13 | 6 | 16 | 16 |
| A year ago | $2.71 | $2.65 | $2.371 | — |
| Growth vs a year ago | +43.6% | +29.9% | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $18.35B | $16.53B | $67.73B | $73.84B |
| Lowest estimate | $18.30B | $16.24B | $67.57B | $71.78B |
| Highest estimate | $18.49B | $17.08B | $67.93B | $75.26B |
| Number of analysts | 11 | 4 | 19 | 19 |
| A year ago | $16.62B | $15.00B | $61.16B | — |
| Growth vs a year ago | +10.4% | +10.2% | +10.7% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for AbbVie Inc.. AbbVie Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AMGNAmgen Inc. | Healthcare | Drug Manufacturers - General | $235.6B | ||
| AZNAstraZeneca PLC | Healthcare | Drug Manufacturers - General | $270.4B | ||
| BMYBristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | $121.7B | ||
| GSKGSK plc | Healthcare | Drug Manufacturers - General | $96.3B | ||
| JNJJohnson & Johnson | Healthcare | Drug Manufacturers - General | $656.5B | ||
| LLYEli Lilly and Company | Healthcare | Drug Manufacturers - General | $1.3T | ||
| MRKMerck & Co., Inc. | Healthcare | Drug Manufacturers - General | $339.7B | ||
| NVSNovartis AG | Healthcare | Drug Manufacturers - General | $284.2B | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| AMRNAmarin Corporation plc | Healthcare | NASDAQ | $222.8M | ||
| BAYRYBayer AG | Healthcare | OTC | $49.0B | ||
| BIIBBiogen Inc. | Healthcare | NASDAQ | $36.9B | ||
| CHGCFChugai Pharmaceutical Co., Ltd. | Healthcare | OTC | $105.3B | ||
| CHGCYChugai Pharmaceutical Co., Ltd. | Healthcare | OTC | $110.0B | ||
| CHJTFCSPC Pharmaceutical Group Limited | Healthcare | OTC | $15.8B | ||
| CSPCYCSPC Pharmaceutical Group Limited | Healthcare | OTC | $14.6B | ||
| DSKYFDaiichi Sankyo Company, Limited | Healthcare | OTC | $34.1B | ||
| DSNKYDaiichi Sankyo Company, Limited | Healthcare | OTC | $36.2B | ||
| FRE.AXFirebrick Pharma Limited | Healthcare | ASX | — | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VOOVanguard S&P 500 ETF | $1.0T in assets | 0.80% | |
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.72% | |
| IVViShares Core SP 500 ETF | $852.9B in assets | 0.81% | |
| SPYState Street SPDR S&P 500 ETF Trust | $818.5B in assets | 0.81% | |
| IYHiShares US Healthcare ETF | $4.7B in assets | 7.62% | |
| HDViShares Core High Dividend ETF | $16.2B in assets | 6.87% | |
| FHLCFIDELITY MSCI HEALTH CARE INDEX ETF | $4.0B in assets | 6.74% | |
| VHTVanguard Health Care ETF | $19.1B in assets | 6.73% | |
Largest holders first, then the funds most concentrated in ABBV.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold AbbVie Inc., and how their positions are changing. At a $505.47B market value, institutional positions materially move AbbVie Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by AbbVie Inc. executives and directors. Shares of AbbVie Inc. have traded between $164.39 and $244.81 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming AbbVie Inc.. AbbVie Inc. is a $505.47B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming AbbVie Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for AbbVie Inc.. Coverage tracks AbbVie Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of AbbVie Inc.